Patrick Petrossians Selected Research

Prolactinoma (Prolactinomas)

4/2019	AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center.
1/2017	Erratum to: Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
1/2017	Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
2/2016	High prevalence of autoimmune thyroid diseases in patients with prolactinomas: A cross-sectional retrospective study in a single tertiary referral centre.
7/2015	Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference.
11/2012	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
11/2010	Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick Petrossians Research Topics

Disease

12	Acromegaly 01/2022 - 01/2005
12	Neoplasms (Cancer) 01/2022 - 01/2005
8	Pituitary Neoplasms (Pituitary Adenoma) 01/2022 - 01/2005
7	Prolactinoma (Prolactinomas) 04/2019 - 11/2010
5	Adenoma (Adenomas) 06/2020 - 01/2005
3	Gigantism 01/2023 - 12/2018
2	Hypothyroidism 03/2022 - 01/2020
2	Cushing Syndrome 01/2022 - 01/2010
2	Disease Progression 12/2019 - 02/2016
2	Hyperprolactinemia 01/2017 - 01/2017
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2010 - 11/2009
1	Goiter 03/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Hyperthyroidism 01/2020
1	Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis) 12/2019
1	Paraganglioma (Paragangliomas) 12/2019
1	Carcinogenesis 12/2019
1	Familial Isolated Pituitary Adenoma 04/2019
1	Endocrine System Diseases (Endocrine Diseases) 01/2017
1	Parkinson Disease (Parkinson's Disease) 01/2017
1	Hyperplasia 06/2015
1	Polyostotic Fibrous Dysplasia (McCune Albright Syndrome) 10/2014
1	Hypertension (High Blood Pressure) 06/2011
1	Genetic Predisposition to Disease (Genetic Predisposition) 03/2011
1	Pituitary ACTH Hypersecretion 01/2010
1	Growth Hormone-Secreting Pituitary Adenoma 01/2005

Drug/Important Bio-Agent (IBA)

6	Insulin-Like Growth Factor I (IGF-1)IBA 01/2022 - 11/2009
6	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 06/2020 - 01/2005
5	ProlactinIBA 02/2016 - 06/2011
4	Growth Hormone (Somatotropin)IBA 01/2022 - 11/2009
4	Cabergoline FDA LinkGeneric 01/2017 - 01/2010
3	Dopamine Agonists (Dopamine Agonist)IBA 01/2017 - 01/2010
2	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2022 - 01/2010
2	LigandsIBA 01/2022 - 01/2020
2	pasireotideIBA 06/2020 - 01/2019
2	pegvisomant FDA LinkGeneric 06/2020 - 11/2009
2	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2020 - 06/2015
2	aryl hydrocarbon receptor-interacting proteinIBA 12/2019 - 10/2011
2	Insulin-Like PeptidesIBA 12/2018 - 06/2012
2	Hormones (Hormone)IBA 11/2016 - 11/2009
1	Mixed Function Oxygenases (Monooxygenases)IBA 01/2023
1	TabletsIBA 03/2022
1	Thyroid HormonesIBA 03/2022
1	lanreotide (Somatuline)FDA Link 12/2021
1	Insulin (Novolin)FDA Link 01/2020
1	Flame Retardants (Fire Retardants)IBA 01/2020
1	Polychlorinated Biphenyls (PCBs)IBA 01/2020
1	2,2',3',4,4',5-hexachlorobiphenylIBA 01/2020
1	Ubiquitin-Specific ProteasesIBA 12/2019
1	Succinate Dehydrogenase (Fumarate Reductase)IBA 12/2019
1	Myc associated factor XIBA 12/2019
1	Cyclin-Dependent Kinase Inhibitor p27IBA 12/2019
1	GTP-Binding Proteins (G-Protein)IBA 10/2014
1	DNA (Deoxyribonucleic Acid)IBA 03/2011
1	Transcription Factors (Transcription Factor)IBA 11/2009

Therapy/Procedure

7	Therapeutics 06/2020 - 01/2005
2	Radiotherapy 11/2010 - 11/2009